Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort. (Registro nro. 17766)
[ vista simple ]
000 -CABECERA | |
---|---|
Campo de control de longitud fija | nab a22 7a 4500 |
003 - IDENTIFICADOR DEL NÚMERO DE CONTROL | |
Campo de control | PC17766 |
005 - FECHA Y HORA DE LA ÚLTIMA TRANSACCIÓN | |
Campo de control | 20231130125059.0 |
008 - CÓDIGOS DE INFORMACIÓN DE LONGITUD FIJA | |
Campo de control de longitud fija | 231130b xxu||||| |||| 00| 0 eng d |
040 ## - FUENTE DE LA CATALOGACIÓN | |
Centro transcriptor | H12O |
041 ## - CÓDIGO DE LENGUA | |
Código de lengua del texto/banda sonora o título independiente | eng |
100 ## - PUNTO DE ACCESO PRINCIPAL - NOMBRE DE PERSONA | |
9 (RLIN) | 1208 |
Nombre de persona | Fernández Vázquez, Inmaculada |
Término indicativo de función | Aparato Digestivo |
245 00 - MENCIÓN DE TÍTULO | |
Título | Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort. |
Tipo de material | [artículo] |
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
Nombre del editor distribuidor etc. | Transplantation proceedings, |
Fecha de publicación distribución etc. | 2016 |
300 ## - DESCRIPCIÓN FÍSICA | |
Extensión | 48(9):3013-6. |
500 ## - NOTA GENERAL | |
Nota general | Formato Vancouver: Sánchez Antolín G, Testillano M, Pascasio JM, Narváez Rodríguez I, Prieto M, Otero A et al; Spanish Society of Liver Transplantation Study Group Collaborating Group. Efficacy and Safety of Therapy With Simeprevir and Sofosbuvir in Liver Transplant Recipients Infected by Hepatitis C Virus Genotype 4: Cohort Spanish Society of Liver Transplantation Cohort. Transplant Proc. 2016 Nov;48(9):3013-6. |
501 ## - NOTA DE “CON” | |
Nota de "Con" | PMID: 27932134 |
504 ## - NOTA DE BIBLIOGRAFÍA; ETC. | |
Nota de bibliografía etc. | Contiene 19 referencias |
520 ## - NOTA DE SUMARIO; ETC. | |
Sumario etc. | Background: Patients with hepatitis C virus (HCV) genotype 4 infection are poorly represented in clinical trials of 2nd-generation direct-acting antivirals (DAAs), and more data are needed to help guide treatment decisions. We still have even fewer data concerning liver transplant patients. Simeprevir (SIM) and sofosbuvir (SOF) combination is useful to treat this genotype. The aim of this study was to know the efficacy and safety of the combination SIM + SOF ± ribavirin (RBV) in a group of liver transplant patients with HCV genotype 4 infection in Spain in real life. Methods: This was a multicenter retrospective study, including 28 HCV genotype 4 patients from 11 liver transplant centers who were treated with SIM + SOF ± RBV. We included in the analysis demographic, clinical, and virologic data and details of serious adverse events (SAEs), including mortality rate 6 months after treatment. Results: All patients were male, mean age 52 ± 9.43 years, and 50% were IL28B CT and 37.5% TT; 46.42% of them were pretreated and 76.9 were null responders. Fibrosis stage 4 was found in 38.7% of patients; in 67.8% of those cases the diagnosis of fibrosis was made with the use of Fibroscan, in 21.4% by liver biopsy. The average Fibroscan was 13.86 KPa. The average Model for End-Stage Liver Disease (MELD) score of cirrhotic patients was 10.9 and the Child-Pugh score was A in 70%, B in 20%, and C in 10%. We included RBV in 75% of patients, and treatment duration was 12 weeks in all patients. The sustained virologic response at week 12 (SVR12) was 95.23%. There were no discontinuations due to SAEs, but the mortality rate at 6 months after treatment was 7.14%. All deceased patients were cirrhotic, Child C, and with an average MELD score of 20. Conclusions: The combination SIM + SOF ± RBV to treat HCV genotype 4 in liver transplant patients is an option with high rates of SVR12 and very safe, similarly to genotype 1. There was no treatment-related mortality, but when it is administered in advanced stages of fibrosis it may not be enough to prevent mortality associated with cirrhotic hepatitis C recurrence after transplantation. |
710 ## - PUNTO DE ACCESO ADICIONAL - NOMBRE DE ENTIDAD | |
9 (RLIN) | 273 |
Nombre de entidad o nombre de jurisdicción como elemento inicial | Servicio de Medicina del Aparato Digestivo |
856 ## - LOCALIZACIÓN Y ACCESO ELECTRÓNICOS | |
Identificador Uniforme del Recurso (URI) | http://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc17766.pdf |
Acceso | Solicitar documento |
942 ## - ENTRADA PARA ELEMENTOS AGREGADOS (KOHA) | |
Fuente de clasificación o esquema de ordenación en estanterías | |
Koha [por defecto] tipo de item | Artículo |
Suprimido en OPAC | Público |
Suprimido | Estado de pérdida | Fuente de clasificación o esquema de ordenación en estanterías | Estropeado | No para préstamo | Localización permanente | Localización actual | Fecha de adquisición | Signatura completa | Fecha última consulta | Fecha del precio de reemplazo | Tipo de item de Koha |
---|---|---|---|---|---|---|---|---|---|---|---|
Hospital Universitario 12 de Octubre | Hospital Universitario 12 de Octubre | 2023-11-30 | PC17766 | 2023-11-30 | 2023-11-30 | Artículo |